Tin t&#x1EE9;c &amp; C&#x1EAD;p nh&#x1EAD;t

Autologous faecal microbiota transfer appears to be a safe procedure in acute myeloid leukaemia (AML) patients undergoing intensive chemotherapy, and seems to effectively restore gut microbiota, a recent study has found.

Autologous faecal microbiota transfer safe, effective for AML patients under intensive chemo

Reproductive factors play role in lung carcinogenesis

Longer fertility span and late menopause appear to contribute to an increased risk of developing lung adenocarcinoma among nonsmoking women, as suggested in a study.

Reproductive factors play role in lung carcinogenesis

Hydrogel spacer protects rectum from radiation during prostate cancer treatment

04 Jun 2021 bởi

Injecting a hydrogel spacer is useful for putting some distance between the rectum and prostate during radiotherapy for prostate cancer, a study reports. As a result, radiation exposure in the rectum is minimized, and late gastrointestinal and genitourinary toxicities are reduced.

Hydrogel spacer protects rectum from radiation during prostate cancer treatment

04 Jun 2021

Short-course nivolumab-ipilimumab shows promise as adjuvant treatment for melanoma

04 Jun 2021

A 6-month course of nivolumab and low-dose ipilimumab appears to be a potential adjuvant treatment for patients with resected melanoma, suggests a study, indicating further research on this regimen.

Short-course nivolumab-ipilimumab shows promise as adjuvant treatment for melanoma

04 Jun 2021

Preoperative chemoradiation ups CV complications risk in oesophageal cancer patients

Operative oesophageal cancer patients treated with preoperative chemoradiation are at increased risk of cardiovascular (CV) complications, reports a study. However, these risks may be lessened with more cardioprotective radiation techniques such as intensity modulated radiotherapy.

Preoperative chemoradiation ups CV complications risk in oesophageal cancer patients

Antibiotics reduce efficacy of immune checkpoint inhibitors

Use of antibiotics during immune checkpoint blockade (ICB) has a significantly negative impact on the efficacy of immunotherapy, reveals a study. The greatest negative impact occurs when using antibiotics in the first 6 weeks after initiating ICB.

Antibiotics reduce efficacy of immune checkpoint inhibitors

Copanlisib-rituximab combo extends PFS in relapsed indolent non-Hodgkin lymphoma

02 Jun 2021 bởi

The combination of copanlisib and rituximab extended progression-free survival (PFS) compared with rituximab alone in patients with relapsed indolent non-Hodgkin lymphoma, results of the phase III CHRONOS-3 trial showed.

Copanlisib-rituximab combo extends PFS in relapsed indolent non-Hodgkin lymphoma

Original New Drug Application Approvals by US FDA (16 - 31 May 2021)

New drug applications approved by US FDA as of 16-31 May 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 May 2021)

NSCLC with EGFR exon 20 mutations: Twice-daily poziotinib clinically active, reduces AEs

02 Jun 2021 bởi

Twice daily (BID) dosing of the irreversible tyrosine kinase inhibitor (TKI) poziotinib demonstrates clinically meaningful activity in treatment-naïve metastatic squamous non-small-cell lung cancer (mNSCLC) patients with EGFR exon 20 mutations, according to results of the phase II multicohort ZENITH20 trial presented at European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021.

NSCLC with EGFR exon 20 mutations: Twice-daily poziotinib clinically active, reduces AEs

FGFR inhibition more effective in cases of fusion or mutation vs amplification

02 Jun 2021 bởi

Retrospective analysis of phase I/II trials targeting solid tumours harbouring FGFR alterations presented at European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021 suggests that FGFR inhibition is more effective in tumours with FGFR fusions or mutations vs FGFR amplification.

FGFR inhibition more effective in cases of fusion or mutation vs amplification